Although no studies have investigated MYL6B in breast cancer, MYL6B overexpression promotes EMT in rectal adenocarcinoma, and in other epithelial cancers, high MYL6B expression is reported as a predictor of poor survival [34]. This evidence concerns the gene MYL6B and breast carcinoma.